Development has been initiated for an anti-SARS-CoV-2 polyclonal hyper-immune globulin (H-IG) to treat high-risk individuals with COVID-19.
SARS-CoV-2 is the virus which causes COVID-19. Plasma derived H-IG therapies have previously shown effectiveness against severe acute viral respiratory infections and may be a treatment option for COVID-19.
The developer is now in discussions with international regulatory authorities from the US, EU and Asia, to advance research on this new treatment. They will need to source plasma from people who were previously infected but have now recovered from the coronavirus, as they would have developed antibodies to the virus that could mitigate the severity of the illness and possible prevent it in future infections. H-IG’s work by concentrating the pathogen-specific antibodies from this recovered plasma, and transferring them to a new patient, thereby helping the new patients’ immune system respond to an infection and increase their chances of recovery.
Along with the development of this H-IG, the pharmaceutical company has announced it is also analysing whether any of its currently marketed and/or pipeline products could be effective in treating infected patients.
“We have identified relevant assets and capabilities across the company and are hopeful that we can expand the treatment options for patients with COVID-19 and the providers caring for them.”
For more information, click here.